Although the North -American rates of imported pharmaceuticals are up to 200% and the food and medicine administration experiences a deep restructuring, the major medicine manufacturers are expanding their domestic biomanfacturing capacity, according to Horizons Report: Life Sciences 2025 and companies’ executives.
The survey of 400 R&D leaders and world manufacturing shows that half of large companies are accelerating investment in US facilities, with 65% pursuing continuous manufacturing systems to increase efficiency.
“It’s not fast political reactions,” said Peter Walters, a CRB partner for advanced therapies. “The buildings take years to plan and validate. What accelerates are now long-term master’s degree projects that were already in motion, but they are replaced to align with the priorities of the United States.”
The tariff climb of the administration of imported medicines has prompted large manufacturers to highlight domestic projects as a gesture towards aligning policies. Walters said that some companies “are re -operating existing investment portfolios” to emphasize United States constructions that could gain a faster rate lens or regulatory coordination.
The data is aligned with the recent movements of the multinational business industry such as Eli Lilly, which announced a $ 2.5 billion installation in Virginia to mitigate exposure to commercial risk.
Related
Virginia wins $ 5 million Eli Lilly Biomanfacture installation
Beyond the rates, Walters said that the largest change is philosophical: production plants are now treated as strategic and flexible infrastructures instead of one product assets.
“Companies spend hundreds of millions in therapies that could never reach commercial scale,” he said. “The facilities must easily pivot: the manipulation of various product profiles or even completely different modalities, so that capital investment does not become the moment when clinical priorities change.”
The CRB report states that 88% of the companies surveyed follow the standardization of processes and modular design to create flexibility between scales and configurations.
Continuous manufacture is approaching an investment point
The most striking finding of the study is the widespread adoption of continuous end -to -end biomanufacture, an approach once experimental now by two thirds of large companies as essential for resilience and sustainability.
“After a decade of incremental advances: perfusion, online filtration, intensified processing, enabled technologies are mature,” said Walters. “Continuous systems allow you to produce more medicines with less space, energy and labor. It is greener, faster and finally cheaper once the capital obstacle has been erased.”
The FDA’s intention to approve small molecules facilities through continuous lines has relieved concern for the regulatory precedent. Walters hopes that the first biological plant on a commercial scale will continue in a couple of years.
While pandemic era projects prioritize calendar, cost discipline now dominates decision -making. Walters said that 47% of respondents listed capital containment as the main driver of the project, with only 11% quoting the speed of the calendar.
Progressive design and objective design design models are gaining traction to align the certainty of the cost between the equipment. “Modularity still makes sense when it saves labor or long -term uses,” he said, “but the market has launched a strong value to value engineering.”
CRB findings echo federal data that show the growth of the available talent biomanfación work. Walters said that companies face “selective shortage”: specialists in valuation and automation have a short supply, even when layoffs reach other functions. This gap, he added, “is pressing design equipment to automate processes and reduce the dependence on human experience that is difficult to find.”
Although North America wins the manufacturing quota, Asia continues to expand quickly in R&D, driven by government investment and bioeconomics initiatives, with Europe maintaining constant growth in initial phase research.
Walters said that the current narrative of restart can be exaggerated: “The global network is not hired; it expands everywhere. What really happens is a rebalancing messaging and risk tolerance.”
Despite economic uncertainty, the horizons data point to continuous expansion. Forty-three percent of the respondents expects global investment to increase by 2026, directed by antibody-fámacs, cell and gene therapies and GPP-1 manufacture.
“The innovation pipeline is as healthy as never before,” Walters said. “The question now is how to build facilities that can adapt -as quickly as science.”
